Navigation Links
HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
Date:3/26/2008

-Agreement provides Lilly researchers broad access to HistoRx AQUA(R)

technology for tissue biomarker analysis-

NEW HAVEN, Conn., March 26 /PRNewswire/ -- HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE: LLY) to make the HistoRx AQUA(R) technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA(R) technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA(R) technology for tissue biomarker analysis, and HistoRx will develop customized AQUA(R) analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.

HistoRx provides pharmaceutical and biotechnology companies access to AQUA(R) technology through partnership agreements by which HistoRx works with the company in applying its hallmark quantitative, multiparametric, tissue- based biomarker measurement and analysis to drug development programs, virtually eliminating the subjective interpretation inherent in conventional immunohistochemical methods. In the course of the partnership, HistoRx develops AQUA(R) analysis-based diagnostic assays that are linked to its partners' drugs in development. HistoRx may then commercialize these assays as prognostic tests or as companion diagnostics.

HistoRx currently has 10 such partnerships with leading pharmaceutical companies such as Lilly involving therapeutics in multiple stages of development. Researchers at these companies are using AQUA(R) analysis-based assays to identify correlations of biomarker expression with clinical outcomes, including drug dosing effects, therapeutic mechanism of action, drug safety, and therapeutic efficacy.

"We consider this expanded agreement with Lilly, one of the world's leading innovation-driven pharmaceutical companies, to be a tremendous validation of the HistoRx AQUA(R) technology," said Rana K. Gupta, CEO of HistoRx. "By revealing stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome, we expect this ongoing partnership to continue providing a substantial boost to Lilly's drug research and development programs."

About HistoRx (http://www.historx.com)

HistoRx, Inc. is a leader in the emerging field of tissue-based diagnostic products for targeted patient treatment. The company's products and services are based on proprietary AQUA(R) technology, the first platform capable of measuring biomarker concentration with subcellular resolution in tissue sections in a fully standardized and automated manner. HistoRx partners with pharmaceutical and biotechnology companies to generate precise and cost- effective answers about the safety and effectiveness of targeted therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop companion diagnostic tests that will be co- marketed with partners' targeted therapeutics. HistoRx also pursues internal programs to develop proprietary diagnostics that will enable improved treatment decisions in cancer care.

CONTACT:

Mary Moynihan

M2Friend Biocommunications

(802) 951-9600

mary@m2friend.com


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lilly Announces Termination of AIR Insulin Program
2. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
6. Lilly Declares Fourth-Quarter Dividend
7. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
8. Neptune Technologies expands into medicinal markets in Asia Pacific
9. CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
10. Nova Biosource Fuels Expands Senior Executive Team
11. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... ... (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) will ... Fla. , The combined scientific sessions offer investigators, clinicians, laboratory technicians, ...
(Date:2/17/2017)... Mass. , Feb. 17, 2017  If ... small tumor had a mutation-conferring resistance to chemotherapy, ... Recently, genomics research has focused on finding these ... or even from circulating tumor DNA in blood ... new oncology therapeutics. Unfortunately, however, detecting ...
(Date:2/16/2017)... PHILADELPHIA , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immune system to find a better treatment for triple negative ... Start in France program. ... is an accelerator designed to help entrepreneurs grow their business ... was one of eight American companies selected to complete an ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
Breaking Biology News(10 mins):